In this article, we have examined the antiproliferative effect of RA and histone deacetylase inhibitor BML-210 on HeLa cells, and particularly the effects on protein expression that may be involved in the cell cycle control and apoptosis. Our data suggest that a combination of RA and BML-210 leads to cell growth inhibition with subsequent apoptosis in a treatment time-dependent manner. We confirm that BML-210 alone or in combination with RA causes a marked increase in the level of p21. The changes in the p53 level are under the influence of p38 phosphorylation. We also discovered that the histone deacetylase inhibitor BML-210 causes increased levels of anti-apoptotic protein Bcl-2 and phosphorylated p38 MAP Kinase; the latter link in cell cycle arrest with response to extracellular stimuli. Our results suggest that RA and BML-210 are involved in different signaling pathways that regulate cell cycle arrest and lead to apoptosis of HeLa cells.
INTRODUCTION
The human papillomavirus (HPV) group presently comprises 67 different virus types that infect epithelial cells and induce hyperproliferative lesions. Oncogenic viruses often exploit the machinery of the cells they infect in order to promote their own survival and replication. As a part of this process, they interfere with normal cellular control mechanisms, leading to abnormal cell growth, genetic alterations, and even malignant transformation. The high-risk HPV types encode three oncoproteins: E5, E6, and E7 where E6 and E7 are involved in cellular immortalization. [1] [2] [3] E6 and E7 genes are transcribed from the HPV early promotor, which is designated p97 in HPV-16 and HPV-31 and p105 in HPV-18.
Moreover E6 and E7 function to stimulate cell proliferation and do so by interfering with the functioning of the regulatory proteins in cells, including the p53 and pRb tumor suppressor gene products. 3, 4 Normally, p53 and Rb control signaling pathways that regulate the cell cycle, but also help monitor and protect cell proliferation and the integrity of hereditary traits on the chromosomes. p53 is a transcription factor activating the expression and transcription of a variety of genes, such as p21, a known p53 responsive gene. p21 is a key regulator of the cell cycle and acts as a universal inhibitor of CDK. 5 The high-risk HPV E6 protein can combine with p53 and, as a result it promotes the ubiquitination and degradation of p53. 6 Retinoids are a group of vitamin A-related compounds that exert potent influences on cell differentiation, proliferation, and development. 7 They can block tumor growth by inhibiting uncontrolled cell proliferation, inducing apoptosis of abnormal cells, and promoting normal cell differentiation. 8 Retinoic acid (RA) can inhibit HPV-16 and -18 in cervical cancer cell lines in vitro by suppressing the transcription of E6 and E7. Previous investigations have shown that retinoic acid receptors (RAR)-mediated repression of HPV-18 E6/E7 transcription occurs through interference with AP-1-mediated activation by RARs. AP-1 is an essential activator of the HPV-18 and -16 enhancers. It is known that AP-1-mediated activation can be repressed by RARs, and conversely RARmediated activation can be blocked by AP-1. Overall, these studies support a direct role of RA in the chemoprevention of HPV-induced cancers. 9, 10 The addition of HDAC inhibitors (HDACI) has been shown to reduce proliferation and to stimulate differentiation and apoptosis in transformed cells in vitro and in vivo. 11 The biological effects of HDACI are mediated by catalyzing the removal of acetyl groups on the NH 2 -terminal lysine residues of core nucleosomal histone; this activity is generally associated with transcriptional repression.
This article was designed to examine the biological effects of HDACI on the cancer cell line HeLa. We focused particularly on BML-210, as a potentially new therapeutic agent in cancer treatment, and its combination with RA. We examined whether these compounds were able to mediate inhibition of cell growth and cell cycle arrest via expression of proteins involved in these processes in a variety of cancer cell lines like HeLa.
MATERIAL AND METHODS

Cell Culture
The HeLa cell line was cultured in Dubecco's modified Eagle's medium (DMEM) (Gibco, Invitrogen, Paisley, UK) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 g/mL streptomycin (Gibco), in 37
• C in humidified air, and 5% CO 2 . Cultures were seeded at a density of 4 × 10 5 cells/mL.
Chemicals
RAs were purchased from Sigma Chem. Co. (St. Louis, MO) and added to the medium from solution of 500 M to a final concentration of 1 M. RA was dissolved in ethanol. BML-210 (BIOMOL, Plymouth Meeting, PA) was dissolved in DMSO (stock solution 10 mM) and added to the medium to a final concentration 5 M or 10 M. The final DMSO concentration in the medium was 0.001%.
Primary Antibodies
Anti-Bcl-2, -p21, -p53, and -Sp1 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and anti-phospho-p38 mitogen-activated protein (MAP) kinase (Thr 180/Tyr 182) and anti-p38 MAP kinase were from Cell Signalling Technology, Inc. (Beverly, CA).
Cell Treatment with All-Trans RA and BML-210
After 24 h from seeding, 1 M of RA or 10 M of BML-210 alone or the combination of 1 M of RA or 5 M BML-210 were added to the medium, and the cells were further grown to 6-7 days.
Immunoblot Analysis
HeLa cells were seeded and grown in the absence or presence of RA and/or BML-210 as indicated. Previously cells were washed twice in ice-cold PBS, were incubated with ice-cold Nuclei EZ lysis buffer (Sigma), scraped off and put on ice for 5 min. Nuclei were collected by centrifugation at 500 g at 4
• C for 5 min and a clear cytoplasmic fraction was obtained by centrifugation of supernatant at 10,000 g at 4
• C for 30 min. Nuclei were then incubated with extraction buffer (20 mM HEPES [pH 7.9], 1.5 mM MgCl 2 , 0.42 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 0.05% NP-40, 25% glycerol) on ice.
Approximately 20 g of protein was fractionated on 8-16% polyacrylamide gradient gel in Tris-glycine electrophoresis buffer. After SDS-PAGE, proteins were transferred to Immobilon TM PVDF membranes (Millipore, Solna, Sweden) and blocked by incubating with 3% BSA dissolved in PBS supplemented with 0.1% Tween-20 at 4
• C overnight. Then the membranes were incubated for 1 h at room temperature with primary antibodies in PBS containing 0.1% Tween-20, 0.35 M NaCl, and 1% BSA. They were subsequently washed for 3 × 10 min with PBS-Tween-20 and incubated with a horseradish peroxidase-conjugated secondary antibody (DAKO, Copenhagen, Denmark) diluted 1:2000 in PBS-Tween-20 for 1 h at room temperature. Thereafter, the filters were washed as described above, and immunoreactive bands were detected by enhanced chemiluminescence (ECL TM Western blotting detection reagents; GE Health Care Amersham Biosciences, Uppsala, Sweden), according to the manufacturer's instructions. And for chemiluminescence detection of p53 and p21 we used SuperSignal West Pico Chemiluminescent Substrate (PIERCE, Rockford, IL), according to the manufacturer's instructions. Reprobing of the membranes, if needed, was done according to the standard ECL Western blotting protocols (GE Health Care Amersham Biosciences).
RESULTS
Distinct Effects of RA and BML-210 on the Proliferation of HeLa Cells
As shown in FIGURE 1, RA, BML-210, and its combination inhibited proliferation of HeLa cells in a time-dependent manner. A 4-day treatment with 1 M RA resulted in about 71% growth inhibition and this inhibition process starts after the second day of treatment. BML-210 alone did not suppress cell growth in comparison with RA-treated cells; cell growth inhibition after 3 days of treatment was observed, compared to untreated control cells. In our experiments, we have examined whether a combination of RA and BML-210 exert a growth-inhibitory effect on Hela cells. When RA and BML-210 were co-administered at concentrations of 1 M and 5 M, respectively, RA boosted the growth-inhibitory effect of BML-210 in HeLa cells so that growth inhibition had already started after 2 days of combined treatment.
Effects of RA and BML-210 on Bcl-2 Expression
Based on previous results showing that RA and BML-210 or in combination inhibit the proliferation of HeLa cells, we investigated the protein expression we prepared the nuclear fraction of HeLa cells after treatment with RA and BML-210 at different time points. We observed an increased level of Sp1 between 48 and 72 h of the treatment with RA, but at 24-48 h during BML-210 treatment and at 24-72 h with RA and BML-210 combination.
Differential Effects of RA and BML-210 on p53, p38, and p21 Protein Expression
Since MAP kinases are involved in many different cellular processes, we examined the p38 protein expression after HeLa cells treatment with RA and BML-210. Using polyclonal antibody raised against total p38 and phosphop38, we demonstrated that p38 in cytoplasmic fraction of HeLa cells become phosphorylated after 24-h treatment with BML-210, on a combination of RA and BML-210 the total protein level of total p-38 remains constant (FIG. 2 A) . With RA the level of phospho-p38 was rather constant between 8 and 24 h and then increased at 48 h of treatment. BML-210 caused phospho-p38 expression level to increase after 24 h, as did the combinatorial treatment with RA and BML-210 (FIG. 2 A) .
To examine the effect of RA and BML-210 on the expression of p53 protein, which is known as a phospho-p38 downregulated protein, HeLa cells were treated with various combinations of RA and BML-210. As shown in FIGURE 2 B an increased level of p53 expression in nuclear fraction was observed at 24 h after treatment with BML-210 alone or in combination with RA. After treatment with RA, the p53 level increased slowly after 24 h and the highest intensity we observed at 96 h of treatment, like in the cytoplasmic fraction (FIG. 2 A) In the cytoplasmic fraction we observed the highest level of p53 protein at 24 h of treatment with BML-210 alone or in combination with RA (FIG. 2 A) .
Since the cyclin-dependent protein kinase inhibitory protein, p21, has been shown to be transcriptionally regulated by p53, we examined whether p53 accumulation also induced changes in p21 protein levels. FIGURE 2 A, B displays the p21 protein in untreated control cells. We found increased p21 protein expression level after treatment with BML-210 alone or in combination with RA at 24-48 h in the cytoplasmic fraction (FIG. 2 A) . We determine an increased p21 protein level at 96 h with RA alone (FIG. 2 A) . The p21 expression level in nuclear fraction had increased at 24 h and then remained more constant (FIG. 2 B) .
DISCUSSION
We first analyzed the effect of RA and BML-210 on growth of HeLa cells, and found that RA and BML-210 alone or in combination induced growth suppression of HeLa cells. With RA present HeLa cell growth was inhibited to a greater extent than with HDACI alone.
To further examine the molecular mechanism of the growth suppression by RA and BML-210, we analyzed the expression of some of the proteins that are involved in a processes such as the inhibition of proliferation and the induction of apoptosis.
Bcl-2 is perhaps the best-characterized member of the bcl-2 family of apoptosis suppressor genes in various cell lines. While the precise physiological role of Bcl-2 has not yet been identified, its overexpression has been shown to protect cells from a variety of otherwise death-inducing stimuli. It has been proposed to play a central role in the regulation of cell growth and apoptotic signaling. [13] [14] [15] We found that a combination of RA and BML-210 led to an earlier increase in Bcl-2 protein expression in comparison with RA or BML-210 alone. It was furthermore shown that in addition to promoting cell cycle arrest, HDACI dramatically induces apoptosis and downregulates bcl-2 expression in lymphomas. The repression of bcl-2 by HDACI occurred at the transcriptional level. Western blot and quantitative chromatin immunoprecipitation (ChIP) assays performed by Duan and co-workers showed that even though HDACI increased overall acetylation of histones, localized histone H3 deacetylation occurred at both bcl-2 promotors. 16 We found that BML-210 after 48 h with RA combination and BML-210 alone decreased Bcl-2 protein level in a cytoplasmic fraction, respectively. These results correlate with the increased p53 protein level in HeLa cells.
p53 is another protein that is very important in cell growth and apoptosis regulation. Since HPV-16 or -18 E6 mediate in the ubiquitin/proteasomedependent degradation of p53 protein, it was pertinent to examine the effects of RA or BML-210 on the p53 expression. 4 Thus, we checked p53 protein expression in the cytoplasmic and nuclear fractions of HeLa cells. HeLa cells contain very little functional p53 activity, but earlier studies have suggested that RA can suppress the transcription of E6 and E7 and increase p53 protein level as well. 17 Our data shows that p53 level indeed increased after treatment with RA, BML-210, and in combination compared to control HeLa cells. Earlier studies have demonstrated that phospho-p38 protein migrates to the nucleus and activates p53 gene transcription. 18 We displayed that increased level of phospho-p38 protein correlates with increased level of p53 protein for the same treatments. Furthermore, we found a correlation between an increased level of p53 and decreased level of Bcl-2 proteins, which could suggest that p53 regulates the degradation of Bcl-2 protein.
MAP kinase cascades are important mediators of the cellular response to a wide variety of extracellular signals, including mitogens, growth factors, cytokines, and cellular stress. The p38 MAP kinases are activated primarily in response to proinflammatory cytokines and cellular stress, such as UV irradiation and osmotic and chemical shock. Activation of p38 occurs by dual phosphorylation on Thr and Tyr amino acids in the p38 kinase domain by an upstream MAP kinase. 19 Since the Sp1 transcription factor can be involved in HPV genes transcription, we analyzed the effect of RA and BML-210 on the Sp1 expression level in HeLa cells. Indeed, the Sp1 protein level changed during treatment with RA, BML-210, or in combination. In both the cytoplasmic and nuclear fractions we detected two bands of Sp1, which represent unphosphorylated and phosphorylated protein forms. Furthermore, Sp1 expression increased after treatment with BML-210 or in combination with RA at 24 h and then decreased after 72 h, in contrast to the constant level of Sp1 after RA treatment. The correlation between cytoplasmic increased level of Bcl-2 at 8 h and nuclear Sp1 at 24 h suggests that the combination of RA and BML-210 activated these signaling proteins earlier than RA or BML-210 alone. By others it has been shown that DNA binding activity of Sp1 correlates with increase in Sp1 phosphorylation, and that Sp1 can be phosphorylated by a number of cellular kinases, including protein kinase A, different members of the protein kinase C family, and ERK2. 12 The gene-encoding p21 is regulated by at least three classes of signals that result in arrest of cell growth: (a) the tumor suppressor protein p53, (b) extracellular growth factors acting in a p53-independent mechanism, 20 and (c) factors that induce cellular differentiation of many cell types such as myoblasts, keratinocytes, intestinal epithelial cells, and monocytes. 21 Other investigators have recently reported the capacity of Sp1 to downregulate p21(WAF1/Cip1) production, thereby reducing p21(WAF1/Cip1)-cyclin D1-Cdk4 complex formation and inhibiting vascular SMC proliferation. 22 The close correlation between the effect of Bcl-2 on both RA-induced growth arrest and RA-induced p21 gene expression suggests the possibility that Bcl-2 affects cell growth through the action of p21. 23 Our data revealed a correlation between Bcl-2 and p21 expression in cytoplasmic fractions of treated HeLa cells after different treatments. For RA the p21 activity correlated with Sp1 activity, but for BML-210 or its combination with RA p53 the increased level correlates with the p21 as well as with the Sp1 level.
In summary, we conclude that BML-210 and a combination of RA with BML-210 affect in a distinct manner the level of proteins that are involved in cell cycle control and growth of HeLa cells. Thus, both BML-210 and RA inhibit cell growth of human cervical cancer HeLa cells and could be important as chemopreventive agents for the treatment of cancer cells.
